CD19-CAR T-cell therapy induces deep tissue depletion of B cellsCarlo Tur, Maria Gabriella Raimondo, Aleix Rius Rigau et al.|Annals of the Rheumatic Diseases|2024Cited by 150
Bispecific T cell engager therapy for refractory rheumatoid arthritisLaura Bucci, Ricardo Grieshaber‐Bouyer, Melanie Hagen et al.|Nature Medicine|2024Cited by 147
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune DiseaseMelanie Hagen, Ricardo Grieshaber‐Bouyer, Laura Bucci et al.|New England Journal of Medicine|2024Cited by 111
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational studyMelanie Hagen, Georg Schett, Fabian Müller et al.|The Lancet Rheumatology|2025Cited by 71
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cellsFabian Müller, Ricardo Grieshaber‐Bouyer, Andreas Wirsching et al.|Nature Medicine|2025Cited by 60